The value of deb-tace as down-stage therapy for hepatocellular carcinoma before liver transplantation
10.3760/cma.j.issn.1007-631X.2019.05.009
- VernacularTitle:载药微球介入栓塞治疗在肝癌肝移植术前降期治疗中的应用
- Author:
Hao WANG
1
;
Guang CHEN
;
Haijun GAO
;
Zhengjia YI
;
Lianfang WEN
;
Penghui WANG
;
Yixin YANG
;
Li ZHANG
;
Qingchan DING
Author Information
1. 天津市第一中心医院放射科 300192
- Keywords:
Carcinoma,hepatocellular;
Liver transplantation;
Drug-eluting beads
- From:
Chinese Journal of General Surgery
2019;34(5):410-412
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the drug-eluting-beads (DEB)-TACE as down-stage therapy for hepatocellular carcinoma before liver transplantation.Methods Inclusion criteria:the hepatocellular carcinoma exceeding the standard of Milan criteria.From Jan 2016 to Jan 2018,30 patients received DEB-TACE as down-stage therapy for hepatocellular carcinoma before liver transplantation.4 weeks after DEB-TACE,the imaging examination was performed.The patients who received the liver transplantation,the pathological conditions were recorded and the tumor free survival of the patients was followed up.Results 30 patients received 30 times DEB-TACE successfully.76.7％ (23/30) patients was down-staged to meet UCSF criteria,53.3％ (16/30) patients was down-staged to meet Milan criteria.13 patients had being given liver transplantation,pathology showed that DEB-TACE achieved complete necrosis in 30.8 ％ (4/13)cases.No significant treatment related complications were observed.After liver transplantation 12 patients are alive with no tumor recurrence.The tumor recurrence rate after liver transplantation was 7.7％.Conclusion DEB-TACE is safe and effective as down-stage therapy for hepatocellular carcinoma before liver transplantation.
